DAS181 dry powder, formulation F02

DRUG3 trials

Sponsors

Ansun Biopharma, Inc.

Conditions

AsthmaBronchiectasisInfluenzaParainfluenza

Phase 1

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

CompletedNCT01113034

Ansun Biopharma, Inc.Asthma, Bronchiectasis

Start: 2010-07-31End: 2011-08-22Updated: 2019-03-27

Phase 2

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

CompletedNCT01037205

Ansun Biopharma, Inc.Influenza

Start: 2009-12-31End: 2011-09-30Updated: 2014-04-08

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

CompletedNCT01644877

Ansun Biopharma, Inc.Parainfluenza

Start: 2014-03-31End: 2016-12-15Updated: 2017-09-25

Related Papers

DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study

Clinical Infectious Diseases2021-02-0527 citations

<i>Pneumocystis</i> Colonization in Asthmatic Patients not Receiving Oral Corticosteroid Therapy

Journal of Investigative Medicine2017-02-147 citations

A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma

BMC Infectious Diseases2015-12-0119 citations

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.

2012-10-08112 citations